Pharmaceutical companies Eli Lilly and Regeneron requested emergency use authorization for separate coronavirus antibody treatments yesterday:
- Eli Lilly requested authorization for its LY-CoV555 treatment after releasing promising results from initial trials last month. The company also announced plans to seek authorization for a combination therapy in November, noting that it reduced hospitalizations in initial trials.
- Regeneron requested authorization for its REGN-COV2 treatment, which was one of several treatments received by President Trump after he was diagnosed with the coronavirus last week.
Extra: Here’s a tracker of vaccines and treatments currently in development.
